Status:
COMPLETED
Repurposing Lithium for Parkinson's Disease
Lead Sponsor:
State University of New York at Buffalo
Collaborating Sponsors:
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Parkinson's Disease
Eligibility:
All Genders
45-80 years
Phase:
PHASE1
Brief Summary
This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.
Detailed Description
In observational studies, small daily doses of lithium have been associated with a 77% reduced risk of developing Parkinson's disease (PD). In addition, lithium therapy has been effective in preventin...
Eligibility Criteria
Inclusion
- Have PD for \<4 years diagnosed by a movement disorder specialist. Have normal thyroid and renal function at the screening visit. Have no previous exposure to lithium therapy. Have no history of brain surgery. Have no hx of brain imaging findings suggesting another neurological condition besides PD.
- Have no use of tobacco or THC products for \>1 year. Have stable PD medications for \>30 days without current need for adjustments in the investigator's opinion.
- Have stable psychiatric and diuretic medications for \>60 days with no anticipated need for changes for at least 24 weeks.
- Have no active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion.
Exclusion
- Have PD for \>4 years or does not have PD. Have abnormal normal thyroid and renal function at the screening visit. Have previous exposure to lithium therapy. Have history of brain surgery. Have hx of brain imaging findings suggesting another neurological condition besides PD.
- Have use of tobacco or THC products within the past year. Have PD medication adjustments within 30 days or needs PD medication adjustments in the investigator's opinion.
- Have psychiatric or diuretic medication adjustments within the last 60 days or is anticipated to need changes over next 24 weeks.
- Have active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion.
Key Trial Info
Start Date :
October 12 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2025
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT06099886
Start Date
October 12 2023
End Date
April 30 2025
Last Update
August 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University at Buffalo
Williamsville, New York, United States, 14221